Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine

Evaxion Biotech A/S EVAX and Pantherna Therapeutics GmbH announced a preclinical proof of concept for combining the two companies key technologies.
The preclinical data demonstrate that tumor neoantigens identified by Evaxion's AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna's proprietary lipid nanoparticle mRNA platform.
In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion's AI platforms.
In November, Evaxion Biotech announced interim safety and immunogenicity data from the Phase 1/2a study of its DNA-based cancer immunotherapy, EVX-02.
EVX-02 is given with a checkpoint inhibitor and targets cancer mutations and neoantigens in patients with resected melanoma.
In December, Evaxion signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate.
Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits cellular and humoral/antibody responses.
EVAX stock was up by 12% at one point in the trading session.
Price Action: EVAX shares are up 1.69% at $1.81 on the last check Wednesday.